Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress

Craig S. Anderson; Anthony Rodgers; H. Asita de Silva; Sheila Ouriques Martins; Catharina JM Klijn; Bimsara Senanayake; Ruth Freed; Laurent Billot; Hisatomi Arima; Nguyen Huy Thang; Wan Asyraf Wan Zaidi; Tinatin Kherkheulidze; Kolawole Wahab; Urs Fisher; Tsong-Hai Lee; Christopher Chen; Octavio M. Pontes-Neto; Thompson Robinson; Jiguang Wang; Sharon Naismith; Lili Song; Floris H Schreuder; Richard I. Lindley; Mark Woodward; Stephen MacMahon; Rustam Al-Shahi Salman; Clara K Chow; John Chalmers; TRIDENT Research Group

doi:10.1177/17474930211068671

Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress

Craig S. Anderson, Anthony Rodgers, H. Asita de Silva, Sheila Ouriques Martins, Catharina JM Klijn, Bimsara Senanayake, Ruth Freed, Laurent Billot, Hisatomi Arima, Nguyen Huy Thang, Wan Asyraf Wan Zaidi, Tinatin Kherkheulidze, Kolawole Wahab, Urs Fisher, Tsong-Hai Lee, Christopher Chen, Octavio M. Pontes-Neto, Thompson Robinson, Jiguang Wang, Sharon NaismithLili Song, Floris H Schreuder, Richard I. Lindley, Mark Woodward, Stephen MacMahon, Rustam Al-Shahi Salman, Clara K Chow, John Chalmers, TRIDENT Research Group

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Background: Patients who suffer intracerebral hemorrhage (ICH) are at very high risk of recurrent ICH and other serious cardiovascular events. A single-pill combination (SPC) of blood pressure (BP) lowering drugs offers a potentially powerful but simple strategy to optimize secondary prevention. Objectives: The Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial (TRIDENT) aims to determine the effects of a novel SPC “Triple Pill,” three generic antihypertensive drugs with demonstrated efficacy and complementary mechanisms of action at half standard dose (telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg), with placebo for the prevention of recurrent stroke, cardiovascular events, and cognitive impairment after ICH. Design: An international, double-blind, placebo-controlled, randomized trial in adults with ICH and mild-moderate hypertension (systolic BP: 130–160 mmHg), who are not taking any Triple Pill component drug at greater than half-dose. A total of 1500 randomized patients provide 90% power to detect a hazard ratio of 0.5, over an average follow-up of 3 years, according to a total primary event rate (any stroke) of 12% in the control arm and other assumptions. Secondary outcomes include recurrent ICH, cardiovascular events, and safety. Results: Recruitment started 28 September 2017. Up to 31 October 2021, 821 patients were randomized at 54 active sites in 10 countries. Triple Pill adherence after 30 months is 86%. The required sample size should be achieved by 2024. Conclusion: Low-dose Triple Pill BP lowering could improve long-term outcome from ICH.

Original language	English
Pages (from-to)	1156-1162
Number of pages	7
Journal	International Journal of Stroke
Volume	17
Issue number	10
DOIs	https://doi.org/10.1177/17474930211068671
Publication status	Published - Dec 2022
Externally published	Yes

Keywords

blood pressure lowering
clinical trial
Hypertension
intracerebral hemorrhage
outcomes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/17474930211068671Licence: In Copyright

Cite this

Anderson, C. S., Rodgers, A., Asita de Silva, H., Martins, S. O., Klijn, C. JM., Senanayake, B., Freed, R., Billot, L., Arima, H., Thang, N. H., Zaidi, W. A. W., Kherkheulidze, T., Wahab, K., Fisher, U., Lee, T.-H., Chen, C., Pontes-Neto, O. M., Robinson, T., Wang, J., ... TRIDENT Research Group (2022). Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress. International Journal of Stroke, 17(10), 1156-1162. https://doi.org/10.1177/17474930211068671

@article{b6545bff8d5246da991cfcd0fe06d8c2,

title = "Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress",

abstract = "Background: Patients who suffer intracerebral hemorrhage (ICH) are at very high risk of recurrent ICH and other serious cardiovascular events. A single-pill combination (SPC) of blood pressure (BP) lowering drugs offers a potentially powerful but simple strategy to optimize secondary prevention. Objectives: The Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial (TRIDENT) aims to determine the effects of a novel SPC “Triple Pill,” three generic antihypertensive drugs with demonstrated efficacy and complementary mechanisms of action at half standard dose (telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg), with placebo for the prevention of recurrent stroke, cardiovascular events, and cognitive impairment after ICH. Design: An international, double-blind, placebo-controlled, randomized trial in adults with ICH and mild-moderate hypertension (systolic BP: 130–160 mmHg), who are not taking any Triple Pill component drug at greater than half-dose. A total of 1500 randomized patients provide 90% power to detect a hazard ratio of 0.5, over an average follow-up of 3 years, according to a total primary event rate (any stroke) of 12% in the control arm and other assumptions. Secondary outcomes include recurrent ICH, cardiovascular events, and safety. Results: Recruitment started 28 September 2017. Up to 31 October 2021, 821 patients were randomized at 54 active sites in 10 countries. Triple Pill adherence after 30 months is 86%. The required sample size should be achieved by 2024. Conclusion: Low-dose Triple Pill BP lowering could improve long-term outcome from ICH.",

keywords = "blood pressure lowering, clinical trial, Hypertension, intracerebral hemorrhage, outcomes",

author = "Anderson, {Craig S.} and Anthony Rodgers and {Asita de Silva}, H. and Martins, {Sheila Ouriques} and Klijn, {Catharina JM} and Bimsara Senanayake and Ruth Freed and Laurent Billot and Hisatomi Arima and Thang, {Nguyen Huy} and Zaidi, {Wan Asyraf Wan} and Tinatin Kherkheulidze and Kolawole Wahab and Urs Fisher and Tsong-Hai Lee and Christopher Chen and Pontes-Neto, {Octavio M.} and Thompson Robinson and Jiguang Wang and Sharon Naismith and Lili Song and Schreuder, {Floris H} and Lindley, {Richard I.} and Mark Woodward and Stephen MacMahon and Salman, {Rustam Al-Shahi} and Chow, {Clara K} and John Chalmers and {TRIDENT Research Group} and Martins, {Sheila O} and Urs Fischer and Peter Sandercock and Eivind Berge and Hankey, {Graeme J.} and Ale Algra and Marieke Wermer and Graham Hillis and Wong, {K.S. Lawrence} and Qiang Li and Xia Wang and Candice Delcourt and {do Espirito Santo}, {Karla Rodrigues} and Cheryl Carcel and Baldeep Kaur and Natalie Espinosa and Joyce Lim and Tina Cheung and Annie Gao and Kathryn Higgins and Grace Balicki and Luke Hatchwell and Manuela Armenis and Magdalen Malone and {de Souza}, {Ana Claudia} and Miyamoto, {Kendi Nishino} and Nodar Kakabadze and Shanny Chen and Bee, {Seu Siow} and Rachel Foo and Tan, {Lee Mei} and Maximus Chien and Curtis Chen and Rinske Hoogland and Adebukunola Telufusi and Faramola Ogunkoya and Cornelius Ibeh and Joseph Onyeanu and Olalekan Oladimeji and Sodiq Salami and Tobi Durojaiye and {Teo Kee Ling}, Connie and Hui Shan and Shalomi Weerawardena and Sadiya Budurdeen and Poornima Ellawala and Namal Wijesinghe and Anuradha Dahanayaka and Thanushanthan Jeevarajah and Seraina Gnanapragasam and Karen Innes and Clare Whittaker and Kelly Stewart and Lynn Dinsmore and Tom Moullaali and Uyen, {Hong Ha} and Tram, {Ngo Thi Bich} and Thu Nguyen and Mai Yen and Le Linh and T. Ang and N. Mitchell and D. Cordato and M Miller and M Kinchington and J. Steel and R. Grimley and E. Witness and K Simmons and D. Ghia and G. Edmonds and KA. Whittaker and M. Ewing and N. Yassi and D. Jackson and H. Brown and C. Bendal and {Mora Cuervo}, D.L. and G. Weiss and C. Batista and E. Reckziegel and T. Secchi and F. Nasi and F. Santos and A. Pille and G.L. Tavares and M. Camilo and R. Arruda and V. Lyra and G. Silva and F.C.D. Barros and D.L. Rodrigues and D. Fagundes and J. Atika and R. Teodoro and K. Alves and R. Bazan and C.H.C. Moro and R. Santos and M. Battaglini and A. Souza and F. Alves and M. Dracoulakis and {Oliveira Lima}, F. and H. Hommem and L. Rebello and T. Silva and V. Z{\'e}tola and M. Lange and V.C. Scavasine and N. Imerlishvili and L. Lursmanashvili and M. Zarandia and I. Kipshidze and M. Beridze and T. Losaberidze and A. Tsiskaridze and N. Lobjanidze and M. Janelidze and N. Bochorishvili and F. Fadzil and I. Looi and Chin, {C. J.} and PD. Suppiah and L.Y. Ng and {Mohd Noor}, J. and {Wan Chung}, L. and A. Steven and WS. Cheng and K.X. Gan and Y.K. Chia and S.H. Chew and KL Koh and S. Abdul-Halim and {Imran Kamarudin}, M. and {Che Rahim}, MJ. and Z. Zakaria and {Malin Abdullah}, J. and Z. Idris and {Wan Hassan}, W.M. and {Mohd Sallehd}, S.Z. and Z. Ismail and A.H. Bello and T.O. Alabi and O. Sanyaolu and A. Bakare and S.A. Adeniyi and R. Obiako and S.A. Abubakar and C. Olurishe and W.E. Oguike and O.G. Osaigbovo and Amusa, {G. A.} and I.S. Joseph and O.B. Olaniru and C. Ugoh and N. Okubadejo and O. Agabi and O. Ojo and B. Amuda-Oladeji and E. Udo and C.R. Opara and R. Akinyemi and E. Uvere and PR. Siongco and V. Nga and A.K. Udenika and I. Rajapakshe and S.R. Inaththappulige and P. Amarasena and A. Kumarasiri and S. Vithoosan and S. Mythily and P.D.D. Karunarathna and A. Rasmi and O.D. Jayasekara and U. Ranawaka and C. Mettananda and D. Munidasa and S. Somaratne and Y.P. Nanayakkara and H. Meegahapola and D. Joseph and H. Gunasekara and G. Wijeratne and B. Kariyawasam and M. Duwani and Z. Liyakath and D. Palliyaguruge and P.J.S. Bandara and S.P. Narayana and J.S. Sumanapala and S.M. Gallage and {Abdul Rasheed}, N. and H. Hordagoda and U. Ralapanawa and B. Subasinghe and T. Rajendiran and S. Alwis and V. Liyanarachchi and N. Gunasekare and J. Peiris and R. Wickramasinghe and C. Fernando and N. Withanage and M. Bandara and D. Wijegunesinghe and S. Wijesena and {De Mel}, M. and D. Abeysinghe and {Wanni Arachchi}, W.A.S.S. and S.D.K. Liyanagamage and A. Keshavaraj and J. Kanagasabapathy and {Gerald Jeevathasan}, A. and J.P. Mathyamuthan and Priyanth, {A. John} and A. Dissanayake and W. Uluwattage and A. Chathurika and C. Rajinee and S. Jayawardana",

year = "2022",

month = dec,

doi = "10.1177/17474930211068671",

language = "English",

volume = "17",

pages = "1156--1162",

journal = "International Journal of Stroke",

issn = "1747-4949",

publisher = "Blackwell Publishing Ltd",

number = "10",

}

Anderson, CS, Rodgers, A, Asita de Silva, H, Martins, SO, Klijn, CJM, Senanayake, B, Freed, R, Billot, L, Arima, H, Thang, NH, Zaidi, WAW, Kherkheulidze, T, Wahab, K, Fisher, U, Lee, T-H, Chen, C, Pontes-Neto, OM, Robinson, T, Wang, J, Naismith, S, Song, L, Schreuder, FH, Lindley, RI, Woodward, M, MacMahon, S, Salman, RA-S, Chow, CK, Chalmers, J & TRIDENT Research Group 2022, 'Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress', International Journal of Stroke, vol. 17, no. 10, pp. 1156-1162. https://doi.org/10.1177/17474930211068671

TY - JOUR

T1 - Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress

AU - Anderson, Craig S.

AU - Rodgers, Anthony

AU - Asita de Silva, H.

AU - Martins, Sheila Ouriques

AU - Klijn, Catharina JM

AU - Senanayake, Bimsara

AU - Freed, Ruth

AU - Billot, Laurent

AU - Arima, Hisatomi

AU - Thang, Nguyen Huy

AU - Zaidi, Wan Asyraf Wan

AU - Kherkheulidze, Tinatin

AU - Wahab, Kolawole

AU - Fisher, Urs

AU - Lee, Tsong-Hai

AU - Chen, Christopher

AU - Pontes-Neto, Octavio M.

AU - Robinson, Thompson

AU - Wang, Jiguang

AU - Naismith, Sharon

AU - Song, Lili

AU - Schreuder, Floris H

AU - Lindley, Richard I.

AU - Woodward, Mark

AU - MacMahon, Stephen

AU - Salman, Rustam Al-Shahi

AU - Chow, Clara K

AU - Chalmers, John

AU - TRIDENT Research Group

AU - Martins, Sheila O

AU - Fischer, Urs

AU - Sandercock, Peter

AU - Berge, Eivind

AU - Hankey, Graeme J.

AU - Algra, Ale

AU - Wermer, Marieke

AU - Hillis, Graham

AU - Wong, K.S. Lawrence

AU - Li, Qiang

AU - Wang, Xia

AU - Delcourt, Candice

AU - do Espirito Santo, Karla Rodrigues

AU - Carcel, Cheryl

AU - Kaur, Baldeep

AU - Espinosa, Natalie

AU - Lim, Joyce

AU - Cheung, Tina

AU - Gao, Annie

AU - Higgins, Kathryn

AU - Balicki, Grace

AU - Hatchwell, Luke

AU - Armenis, Manuela

AU - Malone, Magdalen

AU - de Souza, Ana Claudia

AU - Miyamoto, Kendi Nishino

AU - Kakabadze, Nodar

AU - Chen, Shanny

AU - Bee, Seu Siow

AU - Foo, Rachel

AU - Tan, Lee Mei

AU - Chien, Maximus

AU - Chen, Curtis

AU - Hoogland, Rinske

AU - Telufusi, Adebukunola

AU - Ogunkoya, Faramola

AU - Ibeh, Cornelius

AU - Onyeanu, Joseph

AU - Oladimeji, Olalekan

AU - Salami, Sodiq

AU - Durojaiye, Tobi

AU - Teo Kee Ling, Connie

AU - Shan, Hui

AU - Weerawardena, Shalomi

AU - Budurdeen, Sadiya

AU - Ellawala, Poornima

AU - Wijesinghe, Namal

AU - Dahanayaka, Anuradha

AU - Jeevarajah, Thanushanthan

AU - Gnanapragasam, Seraina

AU - Innes, Karen

AU - Whittaker, Clare

AU - Stewart, Kelly

AU - Dinsmore, Lynn

AU - Moullaali, Tom

AU - Uyen, Hong Ha

AU - Tram, Ngo Thi Bich

AU - Nguyen, Thu

AU - Yen, Mai

AU - Linh, Le

AU - Ang, T.

AU - Mitchell, N.

AU - Cordato, D.

AU - Miller, M

AU - Kinchington, M

AU - Steel, J.

AU - Grimley, R.

AU - Witness, E.

AU - Simmons, K

AU - Ghia, D.

AU - Edmonds, G.

AU - Whittaker, KA.

AU - Ewing, M.

AU - Yassi, N.

AU - Jackson, D.

AU - Brown, H.

AU - Bendal, C.

AU - Mora Cuervo, D.L.

AU - Weiss, G.

AU - Batista, C.

AU - Reckziegel, E.

AU - Secchi, T.

AU - Nasi, F.

AU - Santos, F.

AU - Pille, A.

AU - Tavares, G.L.

AU - Camilo, M.

AU - Arruda, R.

AU - Lyra, V.

AU - Silva, G.

AU - Barros, F.C.D.

AU - Rodrigues, D.L.

AU - Fagundes, D.

AU - Atika, J.

AU - Teodoro, R.

AU - Alves, K.

AU - Bazan, R.

AU - Moro, C.H.C.

AU - Santos, R.

AU - Battaglini, M.

AU - Souza, A.

AU - Alves, F.

AU - Dracoulakis, M.

AU - Oliveira Lima, F.

AU - Hommem, H.

AU - Rebello, L.

AU - Silva, T.

AU - Zétola, V.

AU - Lange, M.

AU - Scavasine, V.C.

AU - Imerlishvili, N.

AU - Lursmanashvili, L.

AU - Zarandia, M.

AU - Kipshidze, I.

AU - Beridze, M.

AU - Losaberidze, T.

AU - Tsiskaridze, A.

AU - Lobjanidze, N.

AU - Janelidze, M.

AU - Bochorishvili, N.

AU - Fadzil, F.

AU - Looi, I.

AU - Chin, C. J.

AU - Suppiah, PD.

AU - Ng, L.Y.

AU - Mohd Noor, J.

AU - Wan Chung, L.

AU - Steven, A.

AU - Cheng, WS.

AU - Gan, K.X.

AU - Chia, Y.K.

AU - Chew, S.H.

AU - Koh, KL

AU - Abdul-Halim, S.

AU - Imran Kamarudin, M.

AU - Che Rahim, MJ.

AU - Zakaria, Z.

AU - Malin Abdullah, J.

AU - Idris, Z.

AU - Wan Hassan, W.M.

AU - Mohd Sallehd, S.Z.

AU - Ismail, Z.

AU - Bello, A.H.

AU - Alabi, T.O.

AU - Sanyaolu, O.

AU - Bakare, A.

AU - Adeniyi, S.A.

AU - Obiako, R.

AU - Abubakar, S.A.

AU - Olurishe, C.

AU - Oguike, W.E.

AU - Osaigbovo, O.G.

AU - Amusa, G. A.

AU - Joseph, I.S.

AU - Olaniru, O.B.

AU - Ugoh, C.

AU - Okubadejo, N.

AU - Agabi, O.

AU - Ojo, O.

AU - Amuda-Oladeji, B.

AU - Udo, E.

AU - Opara, C.R.

AU - Akinyemi, R.

AU - Uvere, E.

AU - Siongco, PR.

AU - Nga, V.

AU - Udenika, A.K.

AU - Rajapakshe, I.

AU - Inaththappulige, S.R.

AU - Amarasena, P.

AU - Kumarasiri, A.

AU - Vithoosan, S.

AU - Mythily, S.

AU - Karunarathna, P.D.D.

AU - Rasmi, A.

AU - Jayasekara, O.D.

AU - Ranawaka, U.

AU - Mettananda, C.

AU - Munidasa, D.

AU - Somaratne, S.

AU - Nanayakkara, Y.P.

AU - Meegahapola, H.

AU - Joseph, D.

AU - Gunasekara, H.

AU - Wijeratne, G.

AU - Kariyawasam, B.

AU - Duwani, M.

AU - Liyakath, Z.

AU - Palliyaguruge, D.

AU - Bandara, P.J.S.

AU - Narayana, S.P.

AU - Sumanapala, J.S.

AU - Gallage, S.M.

AU - Abdul Rasheed, N.

AU - Hordagoda, H.

AU - Ralapanawa, U.

AU - Subasinghe, B.

AU - Rajendiran, T.

AU - Alwis, S.

AU - Liyanarachchi, V.

AU - Gunasekare, N.

AU - Peiris, J.

AU - Wickramasinghe, R.

AU - Fernando, C.

AU - Withanage, N.

AU - Bandara, M.

AU - Wijegunesinghe, D.

AU - Wijesena, S.

AU - De Mel, M.

AU - Abeysinghe, D.

AU - Wanni Arachchi, W.A.S.S.

AU - Liyanagamage, S.D.K.

AU - Keshavaraj, A.

AU - Kanagasabapathy, J.

AU - Gerald Jeevathasan, A.

AU - Mathyamuthan, J.P.

AU - Priyanth, A. John

AU - Dissanayake, A.

AU - Uluwattage, W.

AU - Chathurika, A.

AU - Rajinee, C.

AU - Jayawardana, S.

PY - 2022/12

Y1 - 2022/12

N2 - Background: Patients who suffer intracerebral hemorrhage (ICH) are at very high risk of recurrent ICH and other serious cardiovascular events. A single-pill combination (SPC) of blood pressure (BP) lowering drugs offers a potentially powerful but simple strategy to optimize secondary prevention. Objectives: The Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial (TRIDENT) aims to determine the effects of a novel SPC “Triple Pill,” three generic antihypertensive drugs with demonstrated efficacy and complementary mechanisms of action at half standard dose (telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg), with placebo for the prevention of recurrent stroke, cardiovascular events, and cognitive impairment after ICH. Design: An international, double-blind, placebo-controlled, randomized trial in adults with ICH and mild-moderate hypertension (systolic BP: 130–160 mmHg), who are not taking any Triple Pill component drug at greater than half-dose. A total of 1500 randomized patients provide 90% power to detect a hazard ratio of 0.5, over an average follow-up of 3 years, according to a total primary event rate (any stroke) of 12% in the control arm and other assumptions. Secondary outcomes include recurrent ICH, cardiovascular events, and safety. Results: Recruitment started 28 September 2017. Up to 31 October 2021, 821 patients were randomized at 54 active sites in 10 countries. Triple Pill adherence after 30 months is 86%. The required sample size should be achieved by 2024. Conclusion: Low-dose Triple Pill BP lowering could improve long-term outcome from ICH.

AB - Background: Patients who suffer intracerebral hemorrhage (ICH) are at very high risk of recurrent ICH and other serious cardiovascular events. A single-pill combination (SPC) of blood pressure (BP) lowering drugs offers a potentially powerful but simple strategy to optimize secondary prevention. Objectives: The Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial (TRIDENT) aims to determine the effects of a novel SPC “Triple Pill,” three generic antihypertensive drugs with demonstrated efficacy and complementary mechanisms of action at half standard dose (telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg), with placebo for the prevention of recurrent stroke, cardiovascular events, and cognitive impairment after ICH. Design: An international, double-blind, placebo-controlled, randomized trial in adults with ICH and mild-moderate hypertension (systolic BP: 130–160 mmHg), who are not taking any Triple Pill component drug at greater than half-dose. A total of 1500 randomized patients provide 90% power to detect a hazard ratio of 0.5, over an average follow-up of 3 years, according to a total primary event rate (any stroke) of 12% in the control arm and other assumptions. Secondary outcomes include recurrent ICH, cardiovascular events, and safety. Results: Recruitment started 28 September 2017. Up to 31 October 2021, 821 patients were randomized at 54 active sites in 10 countries. Triple Pill adherence after 30 months is 86%. The required sample size should be achieved by 2024. Conclusion: Low-dose Triple Pill BP lowering could improve long-term outcome from ICH.

KW - blood pressure lowering

KW - clinical trial

KW - Hypertension

KW - intracerebral hemorrhage

KW - outcomes

UR - http://www.scopus.com/inward/record.url?scp=85122729226&partnerID=8YFLogxK

UR - http://purl.org/au-research/grants/NHMRC/1149987

UR - http://purl.org/au-research/grants/NHMRC/1103886

U2 - 10.1177/17474930211068671

DO - 10.1177/17474930211068671

M3 - Article

SN - 1747-4949

VL - 17

SP - 1156

EP - 1162

JO - International Journal of Stroke

JF - International Journal of Stroke

IS - 10

ER -

Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this